The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Shaji KumarDuring the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Multiple Myeloma Hub spoke to Shaji Kumar, Mayo Clinic, Rochester, US, about how to treat patients with triple-class refractory MM.
How to treat triple-class refractory MM?
Despite the introduction of several new classes of drugs in the MM setting, which have resulted in improved depth and duration of remission, the disease relapses in a proportion of patients. Increased understanding of the genetic evolution of MM cells might allow for effective disease control through treatment with combination regimens.
Here, Shaji Kumar outlines the different treatment approaches to triple-class refractory MM, including the newly available agents selinexor and belantamab mafodotin, as well as emerging therapies, including venetoclax, melflufen, and immunotherapy.